NEW INDICATIONS

Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC

JHOP - April 2021 Vol 11, No 2 - FDA Updates, Lung Cancer
Download PDF

On March 3, 2021, the FDA approved a new indication for lorlatinib (Lorbrena; Pfizer), a third-generation ALK inhibitor, for the first-line treatment of patients with non–small-cell lung cancer (NSCLC) and ALK mutation.

The FDA has previously approved lorlatinib based on the CROWN study for the second- or third-line treatment of patients with ALK-positive NSCLC, as detected by an FDA-approved test. This new indication also converts the previous accelerated approval to a full approval.

The expanded indication for lorlatinib was based on the results from the phase 3 CROWN clinical trial, which compared lorlatinib and crizotinib (Xalkori) in treatment-naïve patients with metastatic, ALK-positive NSCLC. The results showed a 72% reduction (hazard ratio, 0.28; 95% confidence interval, 0.19-0.41; P <.0001) in the risk for disease progression or death with lorlatinib versus crizotinib.

“The CROWN data have shown Lorbrena can significantly improve outcomes in the first-line treatment of ALK-positive non-small cell lung cancer, including those who present with brain metastases,” said Benjamin Solomon, MD, Department of Medical Oncology, Peter MacCallum Cancer Centre. “This approval is meaningful for my patients, because we now have a highly effective treatment option that can delay the progression of a typically aggressive disease.”

The most common (≥20%) adverse events of any grade with lorlatinib were edema, weight gain, peripheral neuropathy, cognitive effects, diarrhea, dyspnea, and hypertriglyceridemia. Treatment discontinuation because of adverse events occurred in 6.7% of people.

Related Items
Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer
Matthew S. Mattila, PharmD, BCPS, BCOP, Joel M. Lundberg, MD, FACP
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in Case Report, Lung Cancer
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Skin Cancer
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Myelosuppression
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lymphoma
Vyxeos Now Indicated for Pediatric Patients with AML
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Leukemia, Pediatric Cancer
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Web Exclusives published on March 2, 2021 in Breast Cancer, FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.